Group 1 - The overall market has seen significant growth in 2023, with 23 funds achieving over 100% returns year-to-date, predominantly in the pharmaceutical sector [1][3] - Among these, 17 funds are focused on innovative drugs, making up over 70% of the "doubling funds," with the top performers including 汇添富香港优势精选混合 (QDII) C at 139.12% [4][6] - Over the past year, a total of 134 funds have doubled their returns, with the top fund, 中信建投北交所两年定开混合 A, achieving a remarkable 207.48% return [4][5] Group 2 - The pharmaceutical sector remains a focal point for investment, with analysts optimistic about the innovative drug market and its potential for continued growth [6][7] - Key stocks in high-performing funds include 三生制药 and 科伦博泰生物-B, which have seen substantial price increases of 428.9% and 138% respectively [6][7] - The outlook for the third quarter suggests ongoing opportunities in the innovative drug space, driven by global collaborations and significant clinical data releases [6][7]

Core Viewpoint - The performance of funds in the first half of the year has been significantly influenced by the strong rally in Hong Kong's innovative pharmaceutical sector, with the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, achieving over 85% returns [1][3]. Fund Performance - As of June 30, 2023, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, recorded a return of 86.00% [2][3]. - Other notable funds include CITIC Construction Investment North Exchange Selection and Great Wall Pharmaceutical Industry Selection, with returns of 82.45% and 75.18% respectively [6]. - The overall performance of the Hong Kong stock market, particularly in the innovative pharmaceutical sector, has been robust, with the Hang Seng Index and Hang Seng Technology Index rising by 20% and 18.68% respectively [3]. Market Trends - The innovative pharmaceutical sector in Hong Kong has been a key driver of fund performance, with many funds heavily invested in this area [4][6]. - The Hang Seng Hong Kong Innovative Pharmaceutical Selection Index has seen a year-to-date increase of 58.95%, indicating strong market interest and growth potential [6][7]. - Analysts predict that the innovative pharmaceutical sector will continue to benefit from policy support and market dynamics, suggesting a favorable outlook for the second half of the year [7][8]. Investment Insights - Fund managers believe that the pharmaceutical industry will experience a recovery in growth due to normalized regulations and increasing domestic medical demand [3][4]. - The current market environment is characterized by a combination of policy benefits, global liquidity, and positive market sentiment, which are expected to sustain the growth of innovative pharmaceutical companies [7][8]. - The disparity in fund performance highlights the importance of strategic investment choices, with some funds underperforming despite being in popular sectors [9].

Core Insights - The active equity funds have shown a dramatic contrast in performance amidst rising capital market volatility, with the first "doubling fund" emerging in the year, igniting market enthusiasm, while new fund issuance remains relatively subdued [1][3] - As of June 13, the "Huitianfu Hong Kong Advantage Selected Mixed A/C" fund achieved a year-to-date return exceeding 100%, becoming a market highlight, while 16 active equity funds have returns over 70% [3][4] - Despite strong performance from some funds, the new issuance of active equity funds has been lackluster, with a total of 299.16 billion yuan raised in new funds this year, accounting for only 6.56% of the total public offering new issuance [5][6] Fund Performance - The first "doubling fund" appeared in the active equity market, with the "Huitianfu Hong Kong Advantage Selected Mixed" fund showing a year-to-date increase of over 100% [3] - Other notable funds include "Changcheng Medical Industry Selected Mixed" with over 87% return and "Yongying Medical Innovation Smart Selection" with over 79% return [3] - The overall average return for active equity funds this year is 2.87%, with a significant disparity of 132.35 percentage points between the best and worst performers [3][4] Fund Issuance - A total of 89 new active equity funds were established this year, with the largest fund being "Oriental Red Core Value Mixed" at 19.91 billion yuan [5][6] - 32 active equity funds had issuance sizes below 1 billion yuan, indicating a trend towards smaller fund launches [5] - The failure of the "Shenwan Lingshin Vision Growth Mixed" fund to meet fundraising conditions highlights challenges in the current market environment [6] Market Outlook - Analysts suggest that the key to breaking the current stagnation in new fund issuance lies in enhancing asset allocation capabilities and improving net value performance [7][8] - The recent reforms in public funds emphasize the alignment of fund company income with investor returns, which may enhance the attractiveness of existing products and instill confidence in new offerings [8] - Future issuance of active equity funds may improve as market conditions stabilize and investor confidence returns, with a focus on optimizing product design and enhancing service quality [8][9]